CELYAD SA/ADR (NASDAQ:CYAD)’s stock price traded down 22.1% during trading on Thursday . The stock traded as low as $9.04 and last traded at $10.00, 935,209 shares traded hands during trading. An increase of 6,886% from the average session volume of 13,387 shares. The stock had previously closed at $12.84.
Several equities research analysts recently commented on the stock. William Blair reissued a “buy” rating on shares of CELYAD SA/ADR in a research note on Wednesday, September 4th. Zacks Investment Research lowered shares of CELYAD SA/ADR from a “buy” rating to a “hold” rating in a research note on Thursday, August 29th. Piper Jaffray Companies dropped their price objective on shares of CELYAD SA/ADR from $41.00 to $25.00 and set an “overweight” rating on the stock in a research note on Friday, July 5th. HC Wainwright reissued a “buy” rating and set a $48.00 price objective on shares of CELYAD SA/ADR in a research note on Monday, August 26th. Finally, ValuEngine raised shares of CELYAD SA/ADR from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $29.00.
The company has a debt-to-equity ratio of 0.09, a current ratio of 3.98 and a quick ratio of 5.36. The firm’s 50 day moving average is $12.56 and its 200 day moving average is $17.17. The firm has a market cap of $131.20 million, a P/E ratio of -2.52 and a beta of 1.20.
An institutional investor recently raised its position in CELYAD SA/ADR stock. Victory Capital Management Inc. increased its holdings in shares of CELYAD SA/ADR (NASDAQ:CYAD) by 2.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 690,181 shares of the company’s stock after acquiring an additional 17,850 shares during the period. Victory Capital Management Inc. owned approximately 6.99% of CELYAD SA/ADR worth $7,917,000 at the end of the most recent reporting period. 7.23% of the stock is owned by institutional investors and hedge funds.
CELYAD SA/ADR Company Profile (NASDAQ:CYAD)
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
See Also: What is an economic bubble?
Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.